Compare Regeneron Pharmaceuticals Inc (REGN) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Sirius XM Holdings Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B), while Sirius XM Holdings Inc trades at $26.52 (market cap $8.87B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.6× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (4.1%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Sirius XM Holdings Inc for 102 Days on average.
| REGN | SIRI | |
|---|---|---|
Market Cap | $76.14B | $8.87B |
Volume | 500,239 | 4,324,672 |
Sector | Health | Media |
52-Week High | $852.03 | $32.59 |
52-Week Low | $557.73 | $19.92 |
Typical Hold Time | 107 Days | 102 Days |
Enterprise Value | $70.85B | $18.16B |
Dividend Yield | 0.51% | 4.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Sirius XM (SIRI) trades at $25.95, down 1.56% with bearish technical signals despite strong analyst support. The company shows mixed earnings performance with Q1 2026 beating expectations but Q2 2026 missing. Fundamentals reveal solid profitability with 10.23% net margin and attractive valuation at P/E of 10.42. Recent developments include a YouTube partnership and strong cash flow growth highlighted in recent conferences.
The stock presents a value opportunity with significant upside to the $34.43 consensus target, though technical weakness and competitive pressures in audio streaming warrant caution. Strong institutional buying and dividend payments provide support, but execution on advertising growth remains critical for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
